Skin gene therapy for acquired and inherited disorders

Histology and Histopathology

Volumn 21, Issue 10-12, 2006, Pages 1233-1247

  Carrretero, M ^a   Escamez M J ^a   Prada, F ^b   Mirones, I ^a   Garcia M ^a   Holguin A ^a   Duarte, B ^a   Podhajcer, O ^b   Jorcano, J L ^a   Larcher, F ^a   Del Río, Marcela ^a  

^a CIEMAT   (Spain)

^b University of Buenos Aires Consejo Nacional de Investigaciones Cientificas y Tecnicas ^*  (Argentina)

Author keywords

Gene therapy; Skin; Tissue engineering

Indexed keywords

ANTIBIOTIC AGENT; BECAPLERMIN; COLLAGEN TYPE 7; COMPLEMENTARY RNA; DEOXYRIBODIPYRIMIDINE PHOTOLYASE; DEOXYRIBONUCLEASE (PYRIMIDINE DIMER); IMMUCEPT; KALININ; KERATINOCYTE GROWTH FACTOR; LAMININ; LAMININ BETA3; LIPOSOME; MBI 226; MIFEPRISTONE; NAKED DNA; OSTEONECTIN; P 113D; PEPTIDE; PIGMENT EPITHELIUM DERIVED FACTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BB; POLYPEPTIDE ANTIBIOTIC AGENT; RAPAMYCIN; RECOMBINANT KERATINOCYTE GROWTH FACTOR; STEROID HORMONE; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

CANCER; CANCER CELL; CANCER PATIENT; CANCER THERAPY; CELL INTERACTION; CELL KILLING; CLINICAL TRIAL; CYSTIC FIBROSIS; DIABETES MELLITUS; DNA MODIFICATION; ENVIRONMENTAL FACTOR; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE INTERACTION; GENE THERAPY; GENETIC DISORDER; GENODERMATOSIS; HEMOPHILIA; HUMAN; HUMAN GENOME PROJECT; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; INFLAMMATORY DISEASE; NONHUMAN; PROTEOMICS; REVIEW; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; SKIN DISEASE; STROMA CELL; VASCULARIZATION; ANIMAL; BIOLOGICAL MODEL; IMMUNE SYSTEM; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; SKIN; TISSUE ENGINEERING; WOUND HEALING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; GENE THERAPY; GENETIC DISEASES, INBORN; HUMANS; IMMUNE SYSTEM; MODELS, BIOLOGICAL; NEOPLASMS; PROTEOMICS; SIGNAL TRANSDUCTION; SKIN; TISSUE ENGINEERING; WOUND HEALING;

EID: 33750358159     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (163)

1. Abramson L.P., Stellmach V., Doll J.A., Cornwell M., Arensman R.M. and Crawford S.E. (2003). Wilms' tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft' model. J. Pediatr. Surg. 38, 336-342.
2. Altavilla D., Saitta A., Cucinotta D., Galeano M., Deodato B., Colonna M., Torre V., Russo G., Sardella A., Urna G., Campo G.M., Cavallari V., Squadrito G. and Squadrito F. (2001). Inhibition of lipid peroxidation restores impaired vascular endothelial growth factor expression and stimulates wound healing and angiogenesis in the genetically diabetic mouse. Diabetes 50, 667-674.
3. Alvarez M.J., Prada F., Salvatierra E., Bravo A.I., Lutzky V.P., Carbone C., Pitossi F.J., Chuluyan H.E. and Podhajoer O.L. (2005). Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. Cancer Res. 65, 5123-5132.
4. Andreadis S.T., Hamoen K.E., Yarmush M.L. and Morgan J.R. (2001). Keratinocyte growth factor induces hyperproliferation and delays differentiation in a skin equivalent model system. FASEB J. 15, 898-906.
5. Andrea C., Swain W.F., Page C.P., Macklin M.D., Slama J., Hatzis D. and Eriksson E. (1994). In vivo transfer and expression of a human epidermal growth factor gene accelerates wound repair. Proc. Natl. Acad. Sci. USA 91, 12188-12192.
6. Arnaudeau-Begard C., Brellier F., Chevallier-Lagente O., Hoeijmakers J., Bernerd F., Sarasin A. and Magnaldo T. (2003). Genetic correction of DNA repair-deficient/cancer-prone xeroderma pigmentosum group C keratinocytes. Hum. Gene Ther. 14, 983-996.
7. Baldeschi C., Gache Y., Rattenholl A., Bouille P., Danos O., Ortonne J.P., Bruckner-Tuderman L. and Meneguzzi G. (2003). Genetic correction of canine dystrophic epidermolysis bullosa mediated by retroviral vectors. Hum. Mol. Genet. 12, 1897-1905.
8. Bals R., Weiner D.J., Meegalla R.L. and Wilson J.M. (1999). Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J. Clin. Invest. 103, 1113-1117.
9. Beer H.D., Longaker M.T. and Werner S. (1997). Reduced expression of PDGF and PDGF receptors during impaired wound healing. J. Invest. Dermatol. 109, 132-138.
10. Bernerd F., Asselineau D., Vioux C., Chevallier-Lagente O., Bouadjar B., Sarasin A. and Magnaldo T. (2001). Clues to epidermal cancer proneness revealed by reconstruction of DNA repair-deficient xeroderma pigmentosum skin in vitro. Proc. Natl. Acad. Sci. USA 98, 7817-7822.
11. Blaese R.M., Culver K.W., Miller A.D., Carter C.S., Fleisher T., Clerici M., Shearer G., Chang L., Chiang Y., Tolstoshev P., Greenblatt J.J., Rosenberg S.A., Klein H., Berger M., Mullen C.A., Ramsey W.J., Muul L., Morgan R.A. and Anderson W.F. (1995). T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 270, 475-480.
12. Bradshaw A.D. and Sage E.H. (2001). SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J. Clin. Invest. 107, 1049-1054.
13. Brauchle M., Fassler R. and Werner S. (1995). Suppression of keratinocyte growth factor expression by glucocorticoids in vitro and during wound healing. J. Invest. Dermatol. 105, 579-584.
14. Briggs J., Chamboredon S., Castellazzi M., Kerry J.A. and Bos T.J. (2002). Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene 21, 7077-7091.
15. Brinkmann V., Foroutan H., Sachs M., Weidner K.M. and Birchmeier W. (1995). Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells. J. Cell Biol. 131, 1573-1586.
16. Brown T.J., Shaw P.A., Karp X., Huynh M.H., Begley H. and Ringuette M.J. (1999). Activation of SPARC expression in reactive stroma associated with human epithelia[ ovarian cancer. Gynecol. Oncol. 75, 25-33.
17. Capt A., Spirito F., Guaguere E., Spadafora A., Ortonne J.P. and Meneguzzi G. (2005). Inherited junctional epidermolysis bullosa in the German Pointer: establishment of a large animal model. J. Invest. Dermatol. 124, 530-535.
18. Carreau M., Quilliet X., Eveno E., Salvetti A., Danos O., Heard J.M., Mezzina M. and Sarasin A. (1995). Functional retroviral vector for gene therapy of xeroderma pigmentosum group D patients. Hum. Gene. Ther. 6, 1307-1315.
19. Carretero M., Del Rio M., Garcia M., Escamez M.J., Mirones I., Rivas L., Balague C., Jorcano J.L. and Larcher F. (2004). A cutaneous gene therapy approach to treat infection through keratinocyte-targeted overexpression of antimicrobial peptides. FASEB J. 18, 1931-1933.
20. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., Gross F., Yvon E., Nusbaum P., Selz F., Hue C., Certain S., Casanova J.L., Bousso P., Deist F.L. and Fischer A. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669-672.
21. Chang D.W., Sanchez L.A., Veith F.J., Wain R.A., Okhi T. and Suggs W.D. (2000). Can a tissue-engineered skin graft improve healing of lower extremity foot wounds after revascularization? Ann. Vasc. Surg. 14, 44-49.
22. Chen M., Kasahara N., Keene D.R., Chan L., Hoeffler W.K., Finlay D., Barcova M., Cannon P.M., Mazurek C. and Woodley D.T. (2002). Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat. Genet. 32, 670-675.
23. Crawford S.E., Stellmach V., Ranalli M., Huang X., Huang L., Volpert O., De Vries G.H., Abramson L.P. and Bouck N. (2001). Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J. Cell Sci. 114, 4421-4428.
24. Clark R.A.F. (1996). The molecular and cellular biology of wound repair. 2nd edition. Plenum Press. New York and London.
25. D'Alessandro M., Morley S.M., Ogden P.H., Liovic M., Porter R.M. and Lane E.B. (2004). Functional improvement of mutant keratin cells on addition of desmin: an alternative approach to gene therapy for dominant diseases. Gene Ther. 11, 1290-1295.
26. Davidson D.J., Currie A.J., Reid G.S., Bowdish D.M., MacDonald K.L., Ma R.C., Hancock R.E. and Speert D.P. (2004). The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J. Immunol. 172, 1146-1156.
27. De Luca M., Albanese E., Bondanza S., Megna M., Ugozzoli L., Molina F., Cancedda R., Santi P.L., Bormioli M., Stella M. and Magliacani G. (1989). Multicentre experience in the treatment of burns with autologous and allogenic cultured epithelium, fresh or preserved in a frozen state. Burns 15, 303-309.
28. De Y., Chen Q., Schmidt A.P., Anderson G.M., Wang J.M., Wooters J., Oppenheim J.J. and Chertov O. (2000). LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 192, 1069-1074.
29. Del Rio M., Larcher F., Serrano F., Meana A., Munoz M., Garcia M., Munoz E., Martin C., Bernad A. and Jorcano J.L. (2002). A preclinicall model for the analysis of genetically modified human skin in vivo. Hum. Gene Ther. 13, 959-968.
30. Del Rio M., Gache Y., Jorcano J.L., Meneguzzi G. and Larcher F. (2004). Current approaches and perspectives in human keratinocyte-based gene therapies. Gene Ther. 11 Suppl 1, S57-63.
31. Del Rio M.D., Larcher F., Meana A., Segovia J., Alvarez A. and Jorcano J. (1999). Nonviral transfer of genes to pig primary keratinocytes. Induction of angiogenesis by composite grafts of modified keratinocytes overexpressing VEGF driven by a keratin promoter. Gene Ther. 6, 1734-1741.
32. Dellambra E., Vailly J., Pellegrini G., Bondanza S., Golisano O., Macchia C., Zambruno G., Meneguzzi G. and De Luca M. (1998). Corrective transduction of human epidermal stem cells in laminin-5-dependent junctional epidermolysis bullosa. Hum. Gene Ther. 9, 1359-1370.
33. Dellambra E., Prislei S., Salvati A.L., Madeddu M.L., Golisano O., Siviero E., Bondanza S., Cicuzza S., Orecchia A., Giancotti F.G., Zambruno G. and De Luca M. (2001). Gene correction of integrin beta4-dependent pyloric atresia-junctional epidermolysis bullosa keratinocytes establishes a role for beta4 tyrosines 1422 and 1440 in hemidesmosome assembly. J. Biol. Chem. 276, 41336-41342.
34. Deodato B., Arsic N., Zentilin L., Galeano M., Santoro D., Torre V., Altavilla D., Valdembri D., Bussolino F., Squadrito F. and Giacca M. (2002). Recombinant AAV vector encoding human VEGF165 enhances wound healing. Gene Ther. 9, 777-785.
35. Detmar M., Brown L.F., Schon M.P., Elicker B.M., Velasco, P., Richard L., Fukumura D., Monsky W., Claffey K.P. and Jain R.K. (1998). Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J. Invest. Dermatol. 111, 1-6.
36. Doll J.A., Stellmach V.M., Bouck N.P., Bergh A.R., Lee C., Abramson L.P., Cornwell M.L., Pins M.R., Borensztajn J. and Crawford S.E. (2003). Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat. Med. 9, 774-780.
37. Eming S.A., Lee J., Snow R.G., Tompkins R.G., Yarmush M.L. and Morgan J.R. (1995). Genetically modified human epidermis overexpressing PDGF-A directs the development of a cellular and vascular connective tissue stroma when transplanted to athymic mice - implications for the use of genetically modified keratinocytes to modulate dermal regeneration. J. Invest. Dermatol. 105, 756-763.
38. Eming S.A., Medalie D.A., Tompkins R.G., Yarmush M.L. and Morgan J.R. (1998). Genetically modified human keratinocytes overexpressing PDGF-A enhance the performance of a composite skin graft. Hum. Gene Ther. 9, 529-539.
39. Eming S.A., Whitsitt J.S., He L., Krieg T., Morgan J.R. and Davidson J.M. (1999). Particle-mediated gene transfer of PDGF isoforms promotes wound repair. J. Invest. Dermatol. 112, 297-302.
40. Erdag G., Medalie D.A., Rakhorst H., Krueger G.G. and Morgan J.R. (2004). FGF-7 expression enhances the performance of bioengineered skin. Mol. Ther. 10, 76-85.
41. Escamez M.J., Garcia M., Larcher F., Meana A., Munoz E., Jorcano J.L. and Del Rio M. (2004). An in vivo model of wound healing in genetically modified skin-humanized mice. J. Invest. Dermatol. 123, 1182-1191.
42. Falanga V. (1993). Chronic wounds: pathophysiologic and experimental considerations. J. Invest. Dermatol. 100, 721-725.
43. Falanga. V. (1998). Apligraf treatment of venous ulcers and other chronic wounds. J. Dermatol. 25, 812-817.
44. Fine J.D., Eady R.A., Bauer E.A., Briggaman R.A., Bruckner-Tuderman L., Christiano A., Heagerty A., Hintner H., Jonkman M.F., McGrath J., McGuire J., Moshell A., Shimizu H., Tadini G. and Uitto J. (2000). Revised classification system for inherited epidermolysis bullosa: Report of the Second International Consensus Meeting on diagnosis and classification of epidermolysis bullosa. J. Am. Acad. Dermatol. 42, 1051-1066.
45. Frank S., Hubner G., Breier G., Longaker M.T., Greenhalgh D.G. and Werner S. (1995). Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J. Biol. Chem. 270, 12607-12613.
46. Franzke C.W., Bruckner P. and Bruckner-Tuderman L. (2005). Collagenous transmembrane proteins: recent insights into biology and pathology. J. Biol. Chem. 280, 4005-4008.
47. Frohm M., Agerberth B., Ahangari G., Stahle-Backdahl M., Liden S., Wigzell H. and Gudmundsson G.H. (1997). The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J. Biol. Chem. 272, 15258-15263.
48. Gache Y., Baldeschi C., Del Rio M., Gagnoux-Palacios L., Larcher F., Lacour J.P. and Meneguzzi G. (2004). Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa. Hum. Gene Ther. 15, 921-933.
49. Galeano M., Deodato B., Altavilla D., Cucinotta D., Arsic N., Marini H., Torre V., Giacca M. and Squadrito F. (2003a). Adeno-associated viral vector-mediated human vascular endothelial growth factor gene transfer stimulates angiogenesis and wound healing in the genetically diabetic mouse. Diabetologia 46, 546-555.
50. Galeano M., Deodato B., Altavilla D., Squadrito G., Seminara P., Marini H., Stagno d'Alcontres F., Colonna M., Calo M., Lo Cascio P., Torre V., Giacca M., Venuti F.S. and Squadrito F. (2003b). Effect of recombinant adeno-associated virus vector-mediated vascular endothelial growth factor gene transfer on wound healing after burn injury. Crit. Care Med. 31, 1017-1025.
51. Gallico G.G. 3rd, O'Connor N.E., Compton C.C., Kehinde O. and Green H. (1984). Permanent coverage of large burn wounds with autologous cultured human epithelium. N. Engl. J. Med. 311, 448-451.
52. Gao Z., Sasaoka T., Fujimori T., Oya T., Ishii Y., Sabit H., Kawaguchi M., Kurotaki Y., Naito M., Wada T., Ishizawa S., Kobayashi M., Nabeshima Y. and Sasahara M. (2005). Deletion of the PDGFR-beta gene affects key fibroblast functions important for wound healing. J. Biol. Chem. 280, 9375-9389.
53. Garcia M., Munoz M., Munoz E., Escamez M.J., Asensio F., Meana A., Larcher F., Jorcano J.L. and Del Rio M. (2003). Adenoviral-mediared VEGF transfer to porcine skin equivalents improves graft take and tissue regeneration in an autologous transplantation model. J. Gene Med. Abstracts of the International Symposium on Molecular Diagnostic and Skin Gene Therapy. 5, S23.
54. Garcia M., Fernandez-Garcia N.I., Rivas V., Carretero, M., Escamez M.J., Gonzalez-Martin A., Medrano E.E., Volpert O., Jorcano J.L., Jimenez B., Larcher F. and Del Rio M. (2004). Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. Cancer Res. 64, 5632-5642.
55. Gerrard A.J., Hudson D.L., Brownlee G.G. and Watt F.M. (1993). Towards gene therapy for haemophilia B using primary human keratinocytes. Nat. Genet. 3, 180-183.
56. Gillis P., Savla U., Volpert O.V., Jimenez B., Waters C.M., Panos R.J. and Bouck N.P. (1999). Keratinocyte growth factor induces angiogenesis and protects endothelial barrier function. J. Cell Sci. 112 (Pt 12), 2049-2057.
57. Gruss C.J., Satyamoorthy K., Berking C., Lininger J., Nesbit M., Schaider H., Liu Z.J., Oka M., Hsu M.Y., Shirakawa T., Li G., Bogenrieder T., Carmeliet P., El-Deiry W.S., Eck S.L., Rao J.S., Baker A.H., Bennet J.T., Crombleholme T.M., Velazquez O., Karmacharya J., Margolis D.J., Wilson J.M., Detmar M., Skobe M., Robbins P.D., Buck C. and Herlyn M. (2003). Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice. J. Invest. Dermatol. 120, 683-692.
58. Hacein-Bey-Abina S., von Kalle C., Schmidt M., Le Deist F., Wulffraat N., McIntyre E., Radford I., Villeval J.L., Fraser C.C., Cavazzana-Calvo M. and Fischer A. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348, 255-256.
59. Hamoen K.E. and Morgan J.R. (2002). Transient hyperproliferation of a transgenic human epidermis expressing hepatocyte growth factor. Cell Transplant. 11, 385-395.
60. Hanahan D. and Weinberg R.A. (2000). The hallmarks of cancer. Cell 100, 57-70.
61. Hansbrough J.F., Boyce S.T., Cooper M.L. and Foreman T.J. (1989). Burn wound closure with cultured autologous keratinocytes and fibroblasts attached to a collagen-glycosaminoglycan substrate. JAMA 262, 2125-2130.
62. Harder J., Bartels J., Christophers E. and Schroder J.M. (2001). Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic. J. Biol. Chem. 276, 5707-5713.
63. Heilborn J.D., Nilsson M.F., Kratz G., Weber G., Sorensen O., Borregaard N. and Stahle-Backdahl M. (2003). The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J. Invest. Dermatol. 120, 379-389.
64. Heldin C.H. and Westermark B. (1999). Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79, 1283-1316.
65. Hengge U. (2001). Initial success with topical immunomodulators. A creme for skin cancer?. MMW Fortschr. Med. 143, 11.
66. Jaakkola P., Ahonen M., Kahari V.M. and Jalkanen M. (2000). Transcriptional targeting of adenoviral gene delivery into migrating wound keratinocytes using FiRE, a growth factor-inducible regulatory element. Gene Ther. 7, 1640-1647.
67. Jacob K., Webber M., Benayahu D. and Kleinman H.K. (1999). Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res. 59, 4453-4457.
68. Jacobsen F., Mittler D., Hirsch T., Gerhards A., Lehnhardt M., Voss B., Steinau H.U. and Steinstraesser L. (2005). Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections. Gene Ther. 12, 1494-1502.
69. Jeschke M.G., Richter G., Hofstadter F., Herndon D.N., Perez-Polo J.R. and Jauch K.W. (2002). Non-viral liposomal keratinocyte growth factor (KGF) cDNA gene transfer improves dermal and epidermal regeneration through stimulation of epithelial and mesenchymal factors. Gene Ther. 9, 1065-1074.
70. Koczulla R., von Degenfeld G., Kupatt C., Krotz F., Zahler S., Gloe T., Issbrucker K., Unterberger P., Zaiou M., Lebherz C., Karl A., Raake P., Pfosser A., Boelkstegers P., Welsch U., Hiemstra P.S., Vogelmeier C., Gallo R.L., Clauss M. and Bals R. (2003). An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest. 111, 1665-1672.
71. Koukourakis M.I., Giatromanolaki A., Brekken R.A., Sivridis E., Getter K.C., Harris A.L. and Sage E.H. (2003). Enhanced expression of SPARC/ osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res. 63, 5376-5380.
72. Kraemer K.H. and DiGiovanna J.J. (2002). Topical enzyme therapy for skin diseases? J. Am. Acad. Dermatol. 46, 463-466.
73. Kuhn U., Terunuma A., Pfutzner W., Foster R.A. and Vogel J.C. (2002). In vivo assessment of gene delivery to keratinocytes by lentiviral vectors. J. Virol. 76, 1496-1504.
74. Lane T.F. and Sage E.H. (1994). The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J. 8, 163-173.
75. Larcher F., Murillas R., Bolontrade M., Conti C.J. and Jorcano J.L. (1998). VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 17, 303-311.
76. Larcher F., Del Rio M., Serrano F., Segovia J.C., Ramirez A., Meana A., Page A., Abad J.L., Gonzalez M.A., Bueren J., Bernad A. and Jorcano J.L. (2001). A cutaneous gene therapy approach to human leptin deficiencies: correction of the murine ob/ob phenotype using leptin-targeted keratinocyte grafts. FASEB J. 15, 1529-1538.
77. Lauer G., Sollberg S., Cole M., Flamme I., Sturzebecher J., Mann K., Krieg T. and Eming S.A. (2000). Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. J. Invest. Dermatol. 115, 12-18.
78. Ledda F., Bravo A.I., Adris S., Bover L., Mordoh J. and Podhajcer O.L. (1997). The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J. Invest. Dermatol. 108, 210-214.
79. Ledda. F., Adris S., Bravo A.I., Kairiyama C., Bover L., Chemajovsky Y., Mordoh J. and Podhajcer O.L. (1997b). Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat. Med. 3, 171-176.
80. Levy L., Broad S., Zhu A.J., Carroll J.M., Khazaal I., Peault B. and Watt F.M. (1998). Optimised retroviral infection of human epidermal keratinocytes: long-term expression of transduced integrin gene following grafting on to SCID mice. Gene Ther. 5, 913-922.
81. Liechty K.W., Nesbit M., Herlyn M., Radu A., Adzick N.S. and Crombleholme T.M. (1999a). Adenoviral-mediated overexpression of platelet-derived growth factor-B corrects ischemic impaired wound healing. J. Invest. Dermatol. 113, 375-383.
82. Liechty K.W., Sablich T.J., Adzick N.S. and Crombleholme T.M. (1999b). Recombinant adenoviral mediated gene transfer in ischemic impaired wound healing. Wound Repair Regen. 7, 148-153.
83. Liotta L.A. (2001). An attractive force in metastasis. Nature 410, 24-25.
84. Liotta L.A. and Kohn E.C. (2001). The microenvironment of the tumour-host interface. Nature 411, 375-379.
85. Llames S.G., Del Rio M., Larcher F., Garcia E., Garcia M., Escamez M.J., Jorcano J.L., Holguin P. and Meana A. (2004). Human plasma as a dermal scaffold for the generation of a completely autologous bioengineered skin. Transplantation 77, 350-355.
86. Llames S.G., Garcia E., Garcia V., Del Rio M., Larcher F., Jorcano J.L., Lopez E., Holguin P., Miralles F., Otero O. and Meana A. (2006). Clinical results of an autologous engineered skin. Cell Tissue Banking 7, 47-53.
87. Lussier C., Sodek J. and Beaulieu J.F. (2001). Expression of SPARC/ osteonectin/BM40 in the human gut: predominance in the stroma of the remodeling distal intestine. J. Cell Biochem. 81, 463-476.
88. Magin T.M., Kaiser H.W., Leitgeb S., Grund C., Leigh I.M., Morley S.M. and Lane E.B. (2000). Supplementation of a mutant keratin by stable expression of desmin in cultured human EBS keratinocytes. J. Cell Sci. 113 Pt 23, 4231-4239.
89. Magnol J.P., Pin D., Palazzi X., Lacour J.P., Gache Y. and Meneguzzi G. (2005). Characterization of a canine model of dystrophic bullous epidermolysis (DBE). Development of a gene therapy protocol. Bull. Acad. Natl. Med. 189, 107-119; discussion 119-121.
90. Marchese C., Chedid M., Dirsch O.R., Csaky K.G., Santanelli F., Latini C., LaRochelle W.J., Torrisi M.R. and Aaronson S.A. (1995). Modulation of keratinocyte growth factor and its receptor in reepithelializing human skin. J. Exp. Med. 182, 1369-1376.
91. Marchetto M.C., Muotri A.R., Burns D.K., Friedberg E.C. and Menck C.F. (2004). Gene transduction in skin cells: preventing cancer in xeroderma pigmentosum mice. Proc. Natl. Acad. Sci. USA 101, 17759-17764.
92. Margolis D.J., Crombleholme T. and Herlyn M. (2000). Clinical protocol: Phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair Regen. 8, 480-493.
93. Margolis D.J., Cromblehome T., Herlyn M., Cross P., Weinberg L., Filip J. and Propert K. (2004). Clinical protocol. Phase I trial to evaluate the safety of H5.020CMV.PDGF-b and limb compression bandage for the treatment of venous leg ulcer: trial A. Hum. Gene Ther. 15, 1003-1019.
94. Margolis D.J., Bartus C., Hoffstad O., Malay S. and Berlin J.A. (2005). Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers. Wound Repair Regen. 13, 531-536.
95. Marti G., Ferguson M., Wang J., Byrnes C., Dieb R., Qaiser R., Bonde P., Duncan M.D. and Harmon J.W. (2004). Electroporative transfection with KGF-1 DNA improves wound healing in a diabetic mouse model. Gene Ther. 11, 1780-1785.
96. Martin P. (1997). Wound healing - aiming for perfect skin regeneration. Science 276, 75-81.
97. McGrath J.A., Gatalica B., Christiano A.M., Li K., Owaribe K., McMillan J. R., Eady R.A. and Uitto J. (1995). Mutations in the 180-kD bullous pemphigoid antigen (BPAG2), a hemidesmosomal transmembrane collagen (COL17A1), in generalized atrophic benign epidermolysis bullosa. Nat. Genet. 11, 83-86.
98. Mecklenbeck S., Compton S.H., Mejia J.E., Cervini R., Hovnanian A., Bruckner-Tuderman L. and Barrandon Y. (2002). A microinjected COL7A1-PAC vector restores synthesis of intact procollagen VII in a dystrophic epidermolysis bullosa keratinocyte cell line. Hum. Gene Ther. 13, 1655-1662.
99. Meric J.B., Rixe O. and Khayat D. (2003). Metastatic malignant melanoma. Drugs Today (Barc). 39 Suppl C, 17-38.
100. Meyer-Ingold W. (1993). Wound therapy: growth factors as agents to promote healing. Trends Biotechnol. 11, 387-392.
101. Morishita R., Aoki M., Hashiya N., Makino H., Yamasakii K., Azuma J., Sawa Y., Matsuda H., Kaneda Y. and Ogihara T. (2004). Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 44, 203-209.
102. Nissen N.N., Polverini P.J., Koch A.E., Volin M.V., Gamelli R.L. and DiPietro L.A. (1998). Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am. J. Pathol. 152, 1445-1452.
103. Nissen N.N., Gamelli R.L., Polverini P.J. and DiPietro L.A. (2003). Differential angiogenic and proliferative activity of surgical and burn wound fluids. J. Trauma. 54, 1205-1211.
104. Nomura I., Goleva E., Howell M.D., Hamid Q.A., Ong P.Y., Hall C.F., Darst M.A., Gao B., Boguniewicz M., Travers J.B. and Leung D.Y. (2003). Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J. Immunol. 171, 3262-3269.
105. Ohlfest J.R., Frandsen J.L., Fritz S., Lobitz P.D., Perkinson S.G., Clark K.J., Nelsestuen G., Key N.S., McIvor R.S., Hackett P.B. and Largaespada D.A. (2005). Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood 105, 2691-2698.
106. Ortega M.R., Ganz T. and Milner S.M. (2000). Human beta defensin is absent in burn blister fluid. Burns 26, 724-726.
107. Ortiz-Urda S., Thyagarajan B., Keene D.R., Lin Q., Fang M., Calos M.P. and Khavari P.A. (2002). Stable nonviral genetic correction of inherited human skin disease. Nat. Med. 8, 1166-1170.
108. Ortiz-Urda S., Thyagarajan B., Keene D.R., Lin Q., Calos M.P. and Khavari P.A. (2003a). PhiC31 integrase-mediated nonviral genetic correction of junctional epidermolysis bullosa. Hum. Gene Ther. 14, 923-928.
109. Ortiz-Urda S., Lin Q., Yant S.R., Keene D., Kay M.A. and Khavari P.A. (2003b). Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer. Gene Ther. 10, 1099-1104.
110. Ortiz-Urda S., Lin Q., Green C.L., Keene D.R., Marinkovich M.P. and Khavari P.A. (2003c). Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J. Clin. Invest. 111, 251-255.
111. Pellegrini G., Ranno R., Stracuzzi G., Bondanza S., Guerra L., Zambruno G., Micali G. and De Luca M. (1999). The control of epidermal stem cells (holoclones) in the treatment of massive full-thickness burns with autologous keratinocytes cultured on fibrin. Transplantation 68, 868-879.
112. Pierce G.F., Yanagihara D., Klopchin K., Danilenko D.M., Hsu E., Kenney W.C. and Morris C.F. (1994). Stimulation of all epithelial elements during skin regeneration by keratinocyte growth factor. J. Exp. Med. 179, 831-840.
113. Podhajcer O.L., Wolf C., Lefebvre O., Segain J.-P., Rouyer N., Stoll I., Rio M.-C., Chambon P. and Basset P. (1996). Comparative expression of the SPARC and stromelysin-3 genes in mammary turmours. Breast 5, 13-20.
114. Pulkkinen L. and Uitto J. (1999). Mutation analysis and molecular genetics of epidermolysis bullosa. Matrix Biol. 18, 29-42.
115. Recchia A., Perani L., Sartori D., Olgiati C. and Mavilio F. (2004). Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol. Ther. 10, 660-670.
116. Reuterdahl C., Sundberg C., Rubin K., Funa K. and Gerdin B. (1993). Tissue localization of beta receptors for platelet-derived growth factor and platelet-derived growth factor B chain during wound repair in humans. J. Clin. Invest. 91, 2065-2075.
117. Rich J.N., Shi Q., Hjelmeland M., Cummings T.J., Kuan C.T., Bigner D.D., Counter C.M. and Wang X.F. (2003). Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J. Biol. Chem. 278, 15951-15957.
118. Robbins P.B., Lin Q., Goodnough J.B., Tian H., Chen X. and Khavari P.A. (2001). In vivo restoration of laminin 5 beta 3 expression and function in junctional epidermolysis bullosa. Proc. Natl. Acad. Sci. USA 98, 5193-5198.
119. Romano Di Peppe S., Mangoni A., Zambruno G., Spinetti G., Melillo G., Napolitano M. and Capogrossi M.C. (2002). Adenovirus-mediated VEGF(165) gene transfer enhances wound healing by promoting angiogenesis in CD1 diabetic mice. Gene Ther. 9, 1271-1277.
120. Ronfard V., Rives J.M., Neveux Y., Carsin H. and Barrandon Y. (2000). Long-term regeneration of human epidermis on third degree burns transplanted with autologous cultured epithelium grown on a fibrin matrix. Transplantation 70, 1588-1598.
121. Rosenberg S.A. (1999). A new era of cancer immunotherapy: converting theory to performance. CA Cancer J. Clin. 49, 70-73, 65.
122. Scheid A., Meuli M., Gassmann M. and Wenger R.H. (2000). Genetically modified mouse models in studies on cutaneous wound healing. Exp. Physiol. 85, 687-704.
123. Schultz C., Lemke N., Ge S., Golembieski W.A. and Rempel S.A. (2002). Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res. 62, 6270-6277.
124. Scott M.G., Davidson D.J., Gold M.R., Bowdish D. and Hancock R.E. (2002). The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J. Immunol. 169, 3883-3891.
125. Seitz C.S., Giudice G.J., Balding S.D., Marinkovich M.P. and Khavari P.A. (1999). BP180 gene delivery in junctional epidermolysis bullosa. Gene Ther. 6, 42-47.
126. Serrano F., Del Rio M., Larcher F., Garcia M., Munoz E., Escamez M.J., Munoz M., Meana A., Bernad A. and Jorcano J.L. (2003). A comparison of targeting performance of oncoretroviral versus lentiviral vectors on human keratinocytes. Hum. Gene Ther. 14, 1579-1585.
127. Setoguchi Y., Jaffe H.A., Danel C. and Crystal R.G. (1994). Ex vivo and in vivo gene transfer to the skin using replication-deficient recombinant adenovirus vectors. J. Invest. Dermatol. 102, 415-421.
128. Shaykhiev R., Beisswenger C., Kaendler K., Senske J., Puechner A., Damm T., Behr J. and Bals R. (2005). The human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am. J. Physiol. Lung Cell. Mol. Physiol. 289, L842-848.
129. Singer A.J. and Clark R.A. (1999). Cutaneous wound healing. N. Engl. J. Med. 341, 738-746.
130. Sorensen O.E., Cowland J.B., Theilgaard-Monch K., Liu L., Ganz T. and Borregaard N. (2003). Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors. J. Immunol. 170, 5583-5589.
131. Sotomayor M.G., Yu H., Antonia S., Sotomayor E.M. and Pardoll D.M. (2002). Advances in gene therapy for malignant melanoma. Cancer Control 9, 39-48.
132. Spielberger R., Stiff P., Bensinger W., Gentile T., Weisdorf D., Kewalramani T., Shea T., Yanovich S., Hansen K., Noga S., McCarty J., LeMaistre C.F., Sung E.C., Blazer B.R., Elhardt D., Chen M.G. and Emmanouilides C. (2004). Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med. 351, 2590-2598.
133. Spirito F., Meneguzzi G., Danos O. and Mezzina M. (2001). Cutaneous gene transfer and therapy: the present and the future. J. Gene Med. 3, 21-31.
134. Spirito F., Capt A., Rio M.D., Larcher F., Guaguere E., Danos O. and Meneguzzi G. (2006). Sustained phenotypic reversion of junctional epidermolysis bullosa dog keratinocytes: Establishment of an immunocompetent animal model for cutaneous gene therapy. Biochem. Biophys. Res. Commun. 339, 769-778.
135. Staiano-Coico L., Krueger J.G., Rubin J.S., D'Limi S., Vallat V.P., Valentino L., Fahey T., 3rd, Hawes A., Kingston G. Madden M.R. Mathwich M., Gottlieb A.B. and Aaronson S.A. (1993). Human keratinocyte growth factor effects in a porcine model of epidermal wound healing. J. Exp. Med. 178, 865-878.
136. Steinstraesser L., Oezdogan Y., Wang S.C. and Steinau H.U. (2004). Host defense peptides in burns. Burns 30, 619-627.
137. Stellmach V., Crawford S.E., Zhou W. and Bouck N. (2001). Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc. Natl. Acad. Sci. USA 98, 2593-2597.
138. Supp D.M. and Boyce S.T. (2002). Overexpression of vascular endothelial growth factor accelerates early vascularization and improves healing of genetically modified cultured skin substitutes. J. Burn Care Rehabil. 23, 10-20.
139. Supp D.M., Bell S.M., Morgan J.R. and Boyce S.T. (2000a). Genetic modification of cultured skin substitutes by transduction of human keratinocytes and fibroblasts with platelet-derived growth factor-A. Wound Repair Regen. 8, 26-35.
140. Supp D.M., Supp A.P., Bell S.M. and Boyce S.T. (2000b). Enhanced
141. Sylvester K.G., Nesbit M., Radu A., Herlyn M., Adzick N.S. and Crombleholme T.M. (2000). Adenoviral-mediated gene transfer in wound healing: acute inflammatory response in human skin in the SCID mouse model. Wound Repair Regen. 8, 36-44.
142. Teumer J., Lindahl A. and Green H. (1990). Human growth hormone in the blood of athymic mice grafted with cultures of hormone-secreting human keratinocytes. FASEB J. 4, 3245-3250.
143. Tombran-Tink J. and Barnstable C.J. (2003). PEDF: a multifaceted neurotrophic factor. Nat. Rev. Neurosci. 4, 628-636.
144. Toniatti C., Bujard H., Cortese R. and Ciliberto G. (2004). Gene therapy progress and prospects: transcription regulatory systems. Gene Ther. 11, 649-657.
145. Uitto J. and Pulkkinen L. (2000). The genodermatoses: candidate diseases for gene therapy. Hum. Gene Ther. 11, 2267-2275.
146. Uitto J. and Richard G. (2004). Progress in epidermolysis bullosa: genetic classification and clinical implications. Am. J. Med. Genet. C Semin. Med. Genet. 131C, 61-74.
147. Uitto J. and Richard G. (2005). Progress in epidermolysis bullosa: from eponyms to molecular genetic classification. Clin. Dermatol. 23, 33-40.
148. Vailly J., Gagnoux-Palacios L., Dell'Ambra E., Romero C., Pinola M., Zambruno G., De Luca M., Ortonne J.P. and Meneguzzi G. (1998). Corrective gene transfer of keratinocytes from patients with junctional epidermolysis bullosa restores assembly of hemidesmosomes in reconstructed epithelia. Gene Ther. 5, 1322-1332.
149. Vidal F., Aberdam D., Miquel C., Christiano A.M., Pulkkinen L., Uitto J., Ortonne J.P. and Meneguzzi G. (1995). Integrin beta 4 mutations associated with junctional epidermolysis bullosa with pyloric atresia. Nat. Genet. 10, 229-234.
150. Vogt P.M., Lehnhardt M., Wagner D., Jansen V., Krieg M. and Steinau H.U. (1998). Determination of endogenous growth factors in human wound fluid: temporal presence and profiles of secretion. Plast. Reconstr. Surg. 102, 117-123.
151. Wang L., Schmitz V., Perez-Mediavilla A., Izal I., Prieto J. and Qian C. (2003). Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Mol. Ther. 8, 72-79.
152. Werner S. (1998). Keratinocyte growth factor: a unique player in epithelial repair processes. Cytokine Growth Factor Rev. 9, 153-165.
153. Werner S. and Grose R. (2003). Regulation of wound healing by growth factors and cytokines. Physiol. Rev. 83, 835-870.
154. Werner S., Peters K.G., Longaker M.T., Fuller-Pace F., Banda M.J. and Williams L.T. (1992). Large induction of keratinocyte growth factor expression in the dermis during wound healing. Proc. Natl. Acad. Sci. USA 89, 6896-6900.
155. Werner S., Breeden M., Hubner G., Greenhalgh D.G. and Longaker M.T. (1994a). Induction of keratinocyte growth factor expression is reduced and delayed during wound healing in the genetically diabetic mouse. J. Invest. Dermatol. 103, 469-473.
156. Werner S., Smola H., Liao X., Longaker M.T., Krieg T., Hofschneider P.H. and Williams L.T. (1994b). The function of KGF in morphogenesis of epithelium and reepithelialization of wounds. Science 266, 819-822.
157. Westphal E.M. and Melchner Hv H. (2002). Gene therapy approaches for the selective killing of cancer cells. Curr. Pharm. Des. 8, 1683-1694.
158. Woodley D.T., Krueger G.G., Jorgensen C.M., Fairley J.A., Atha T., Huang Y., Chan L., Keene D.R. and Chen M. (2003). Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J. Invest. Dermatol. 121, 1021-1028.
159. Woodley D.T., Keene D.R., Atha T., Huang Y., Ram R., Kasahara N. and Chen M. (2004a). Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo. Mol. Ther. 10, 318-326.
160. Woodley D.T., Keene D.R., Atha T., Huang Y,, Lipman K., Li W. and Chen M. (2004b). Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat. Med. 10, 693-695.
161. Xue S., Gillmore R., Downs A., Tsallios A., Holler A., Gao L., Wong V., Morris E. and Stauss H.J. (2005). Exploiting T cell receptor genes for cancer immunotherapy. Clin. Exp. Immunol. 139, 167-172.
162. Yarosh D., Klein J., O'Connor A., Hawk J., Rafal E. and Wolf P. (2001). Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group. Lancet 357, 926-929.
163. Zeng L., Quilliet X., Chevallier-Lagente O., Eveno E., Sarasin A. and Mezzina M. (1997). Retrovirus-mediated gene transfer corrects DNA repair defect of xeroderma pigmentosum cells of complementation groups A, B and C. Gene Ther. 4, 1077-1084.